• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices

Exact Sciences Corp.

Thrive raises $257m for CancerSeek

July 29, 2020 By Tom Salemi

Investors once again lined up behind Thrive Earlier Detection and its potentially revolutionary cancer diagnostic The one-year-old start raised a $257 million Series B round from a syndicate of venture and crossover investors, including round leaders Casdin Capital and Section 32 and new investors Bain Capital Life Sciences, Brown Advisory, Driehaus Capital Management, Intermountain Ventures, […]

Filed Under: Blood Management, Clinical Trials, Device Talks Podcasts, Diagnostics, Featured, Oncology Tagged With: Exact Sciences Corp., Geisinger Health System, Johns Hopkins University, Thrive Earlier Detection Corp.

How Exact Sciences built a DNA screening test for colorectal cancer

October 28, 2015 By Brian Johnson

In a seemingly endless war on cancer, the best weapon remains early detection, according to Graham Lidgard, senior vice president of R&D at Exact Sciences Corp. For Lidgard, and the rest of the team at the Madison, Wisc.-based molecular diagnostics maker, the battlefield is colorectal cancer, 1 of the most common, and deadliest, cancers in […]

Filed Under: Device Talks Podcasts, Diagnostics, Oncology Tagged With: Exact Sciences Corp.

Exact Sciences lands 1st joint approval through FDA-CMS parallel review

August 13, 2014 By Arezu Sarvestani Leave a Comment

Exact Sciences lands 1st joint approval through FDA-CMS parallel review

Wisconsin-based Exact Sciences (NSDQ:EXAS) won landmark approval for its Cologuard home colorectal cancer test, becoming the 1st company to successfully navigate a pilot program for parallel review by both FDA and Medicare regulators.

Filed Under: Food & Drug Administration (FDA), Genomics/Molecular Diagnostics, Medicare, News Well, Oncology, Pre-Market Approval (PMA), Regulatory/Compliance Tagged With: Center for Devices and Radiological Health (CDRH), Centers for Medicare and Medicaid Services (CMS), Exact Sciences Corp.

Press Release: FDA approves first non-invasive DNA screening test for colorectal cancer

August 13, 2014 By Arezu Sarvestani Leave a Comment

Press Release: FDA approves first non-invasive DNA screening test for colorectal cancer

The U.S. Food and Drug Administration today approved Cologuard, the first stool-based colorectal screening test that detects the presence of red blood cells and DNA mutations that may indicate the presence of certain kinds of abnormal growths that may be cancers such as colon cancer or precursors to cancer.

Filed Under: Food & Drug Administration (FDA), Genomics/Molecular Diagnostics, Medicare, News Well, Oncology, Pre-Market Approval (PMA), Regulatory/Compliance Tagged With: Center for Devices and Radiological Health (CDRH), Centers for Medicare and Medicaid Services (CMS), Exact Sciences Corp., Press Release

Insulet’s Q4 losses widen but 2010 losses fall 16 percent | Earnings roundup

February 16, 2011 By MassDevice staff Leave a Comment

MassDevice.com Earnings Roundup

MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.

Here’s a quick rundown of a few releases over the past couple days:

Filed Under: Business/Financial News, MassDevice Earnings Roundup, News Well Tagged With: AdvanSource Biomaterials Corp., American Medical Systems Holdings Inc., ArthroCare Corp., Corgenix Medical Corp., DJO Global, Dynatronics Corp, Exact Sciences Corp., Gen-Probe Inc., Insulet, IsoRay, Masimo, Orthofix, Q4, Theragenics Corp., Unilife Corp.

Two accused in insider trading of molecular diagnostics stocks

December 13, 2010 By MassDevice staff Leave a Comment

EXAS, Sequenom logos

The federal Securities & Exchange Commission charged a Baltimore business consultant and his uncle in Cleveland of an insider trading scheme that netted the pair more than $600,000.

Filed Under: Business/Financial News, Diagnostics, Genomics/Molecular Diagnostics, Legal News, News Well Tagged With: Exact Sciences Corp., Sequenom Inc.

Exact Sciences registers $150 million securities sale

August 19, 2010 By MassDevice staff Leave a Comment

EXAS logo

Exact Sciences Corp. (NSDQ:EXAS) filed a shelf registration statement for the sale of up to $150 million in equity, debt and warrants, according to the federal Securities & Exchange Commission.

In a press release, the Madison, Wis.-based molecular diagnostics developer said it does not have immediate plans to offer the securites, but wants to keep its options open.

Filed Under: Business/Financial News, Diagnostics, Genomics/Molecular Diagnostics, News Well Tagged With: Exact Sciences Corp.

Exact Sciences has steady revenue, losses

July 28, 2010 By MassDevice staff Leave a Comment

EXAS logo

Exact Sciences Corp.’s (NSDQ:EXAS) net losses for its 2010 second quarter were almost double the company’s revenues, but still less than during the same period last year.

The company reported a net loss of $2.5 million, or 6 cents per diluted share, on revenues of $1.3 million during the three months ended June 30. Those results compare with a net loss of $2.4 million, or 8 cents per diluted share, on sales of $1.3 million during Q2 2009.

Filed Under: Business/Financial News, Diagnostics, Genomics/Molecular Diagnostics, MassDevice Earnings Roundup, News Well Tagged With: Exact Sciences Corp.

Exact Sciences inks biomarkers deal with Belgian firm

July 27, 2010 By MassDevice staff Leave a Comment

EXAS logo

Exact Sciences Corp. (NSDQ:EXAS) inked a licensing deal with Belgium-based OncoMethylome Sciences for that company’s DNA methylation biomarkers.

The Madison, Wis.-based company gained exclusive worldwide rights for up to two of OncoMethylome’s biomarkers utilized in its stool-based detection of colorectal cancer, the companies said.

Filed Under: Business/Financial News, Diagnostics, Genomics/Molecular Diagnostics, News Well, Oncology Tagged With: Exact Sciences Corp.

Exact Sciences posts Q4 revenue gains, narrows losses

February 16, 2010 By MassDevice staff Leave a Comment

Exact Sciences Corp. (NSDQ:EXAS) posted fourth-quarter sales of $1.2 million for the three months ended Dec. 31, 2009, compared with negative revenues of $109,000 during the same period in 2008. Net losses narrowed 13.9 percent to $1.8 million, compared with $2.1 million during Q4 2008:

Filed Under: Business/Financial News, Diagnostics, MassDevice Earnings Roundup, News Well, Oncology Tagged With: Exact Sciences Corp.

Quest Diagnostics launches blood test for colorectal cancer

January 12, 2010 By MassDevice staff Leave a Comment

Quest Diagnostics Inc. (NYSE:DGX) introduced a new blood test with the potential to identify colorectal cancer by detecting chemical changes in specific strands of genetic material.

Quest Diagnostics plans to market its new ColoVantage test as a supplement to other screening tools such as colonoscopy and fecal occult blood tests. Company officials said in prepared remarks that while ColoVantage has not yet been clinically validated, they hope the relative ease of a blood test would convince individuals who previously have passed on more invasive tests to be screened.

Filed Under: Business/Financial News, Diagnostics, Genomics/Molecular Diagnostics, News Well Tagged With: Epigenomics AG, Exact Sciences Corp., OncoMethylome Sciences Inc., Quest Diagnostics Inc.

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy